PTOISB/08x (08-03)
Approved for use through 07/31/2006 (OMD 0851-0201
U.S. Pistent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless of contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to resp

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10615791	
Filing Date		2003-07-10	
First Named Inventor Take		shi Shiota	
Art Unit		2613	
Examiner Name			
Attamen Dealest Nomb	~	030762	

				Attorn	ey Doc	ket Number		030762				
					U.S.	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Pate of cited Docu		ee or Applicant ent	Relev		Lines where ges or Relev	
	1											
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Ad	id button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	JC	ATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu		ee or Applicant ent	Relev		Lines where ges or Relev	
	1											
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	le	ase click the Ad	d buttor	n. Add		
				FOREIG	SN PAT	TENT DOCUM	ΕN	ITS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country	y Code ²	Kind Code4	Publication Date	A	ame of Patente pplicant of cited locument	e or	where Rel	or Relevant	74
	1	1164230	JP			1999-03-05	s	Shibazaki Denshi i	KK			V
	2	1117757	JP			1989-08-09		Mitsubishi Heavy ndustries, Ltd.				
If you wish	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	ea	se click the Add	button	Add		
			NON	I-PATEN	IT LITE	RATURE DO	CU	IMENTS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)									
		First Named Inventor Takeshi Shiota		shi Shiota					
		Art Unit		2613					
		Examiner Name							
				Attorney Docket Numb	er	030762			
	Examiner Cite Initials* Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								

10615791

2003-07-10

V

Application Number

Filing Date

Notification for Reasons for Refusal dated December 6, 2005

EXAMINER SIGNATURE								
	Examiner Signature		Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw I citation if not in conformance and not considered. Include copy of this form with next communication to applic								

If you wish to add additional non-patent literature document citation information please click the Add button Add

1-Sex for Codes or USPTO Patent Documents at www.USPTO.GOV or MPEP 90.04. 2 Enter office that issued the document, by the two-letter code (NIPC Standard ST3.). 2 For Justice points of your or the beginning of the standard ST3.). 2 For Justice points of your or the period of the standard ST3. 2 For Justice points of your or the standard ST3. 4 For Justice Points of the ST3. 2 For Justice Points of the ST3. 2 For Justice Points of the ST3. 2 For Justice Points of the ST3. 4 For Justice Points

	Application Number		10615791
_	Filing Date		2003-07-10
E T	First Named Inventor Take		shi Shiota
)	Art Unit		2613
,	Examiner Name		
	Attorney Docket Number		030762

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appropria	te selection(s)

That each item of information contained in the information disclosure statement was first cited in any communication \overline{Q} from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

That no item of informa	tion contained in th	e information disclosure	statement was cited in	a communication from a

OR

INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Not for submission under 37 CFR 1.9)

	foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, or team of Information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.
-	See attached certification statement.

- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- The section in 57 of K 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/William F. Westerman/	Date (YYYY-MM-DD)	2006-02-08
Name/Print	William F. Westerman	Registration Number	29988

This collection of Information is required by 3T CFR 1.37 and 1.98. The information is required to obtain or retain a benefit by the public which is to fice and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradent Affice, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA.2213-1450. DO NOT SEND FIES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.